Williams, Robert O.

Caveolin-1–derived peptide limits development of pulmonary fibrosis

Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisCaveolin-1 and cellular processes

Cited by 86

Single dose and multiple dose studies of itraconazole nanoparticles

Vaughn, J. M., McConville, J. T., Burgess, D., Peters, J. I., Johnston, K. P., Talbert, R. L., & Williams, R. O. (2006) · European Journal of Pharmaceutics and Biopharmaceutics

Inhalation and Respiratory Drug DeliveryAdvanced Drug Delivery Systems

Cited by 85

Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis

Alvarez, C. A., Wiederhold, N. P., McConville, J. T., Peters, J. I., Najvar, L. K., Graybill, J. R., Coalson, J. J., Talbert, R. L., Burgess, D. S., Bocanegra, R., et al. (2007) · Journal of Infection

Antifungal resistance and susceptibilityInhalation and Respiratory Drug Delivery

Cited by 43

Development of an Excipient-Free Peptide Dry Powder Inhalation for the Treatment of Pulmonary Fibrosis

Zhang, Y., MacKenzie, B., Koleng, J. J., Maier, E., Warnken, Z. N., & Williams, R. O. (2020) · Molecular Pharmaceutics

Inhalation and Respiratory Drug DeliveryInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 27

p53-miR-34a feedback in lung fibroblasts regulates antifibrotic effects of CSP7, nintedanib, and pirfenidone

Fan, L., Shetty, R. S., Dao, H. M., Balnadupete, A., Somasundram, B., Bhagavath, A. K., Kongara, A., Tang, H., Citrin, D. E., Williams, R. O., et al. (2025) · American Journal of Physiology-Lung Cellular and Molecular Physiology

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments

Cited by 3